Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEMNYSE:DNAOTCMKTS:IPHYFNASDAQ:RLAY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGEMCullinan Therapeutics$7.76+0.1%$8.16$6.85▼$21.01$457.96M-0.04520,656 shs1.44 million shsDNAGinkgo Bioworks$9.42-2.0%$7.89$5.00▼$16.85$553.71M1.251.43 million shs7.04 million shsIPHYFInnate Pharma$1.95$1.54$1.45▼$1.95$163.47M0.465 shsN/ARLAYRelay Therapeutics$3.30-0.6%$3.13$1.78▼$10.72$565.77M1.592.09 million shs2.08 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGEMCullinan Therapeutics0.00%+1.17%-10.60%-3.24%-52.97%DNAGinkgo Bioworks0.00%+10.36%+30.16%+52.97%-55.45%IPHYFInnate Pharma0.00%+12.39%+34.48%-32.76%-21.69%RLAYRelay Therapeutics0.00%+3.45%+7.14%+21.32%-47.28%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGEMCullinan Therapeutics2.1938 of 5 stars3.51.00.00.02.71.70.6DNAGinkgo Bioworks0.7815 of 5 stars0.82.00.00.01.82.51.3IPHYFInnate Pharma0.0915 of 5 stars0.02.00.00.00.01.70.0RLAYRelay Therapeutics2.8821 of 5 stars3.42.00.00.03.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGEMCullinan Therapeutics 3.00Buy$30.00286.60% UpsideDNAGinkgo Bioworks 1.67Reduce$5.77-38.76% DownsideIPHYFInnate Pharma 0.00N/AN/AN/ARLAYRelay Therapeutics 2.83Moderate Buy$17.67435.35% UpsideCurrent Analyst Ratings BreakdownLatest IPHYF, DNA, CGEM, and RLAY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025CGEMCullinan TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$22.005/12/2025CGEMCullinan TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $24.005/7/2025RLAYRelay TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $10.004/17/2025RLAYRelay TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$4.004/16/2025CGEMCullinan TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $33.00(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGEMCullinan TherapeuticsN/AN/AN/AN/A$10.14 per shareN/ADNAGinkgo Bioworks$227.04M2.43N/AN/A$13.17 per share0.72IPHYFInnate Pharma$21.77M7.51N/AN/A$0.11 per share17.73RLAYRelay Therapeutics$10.01M56.52N/AN/A$4.65 per share0.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGEMCullinan Therapeutics-$167.38M-$2.91N/AN/AN/AN/A-29.47%-28.19%8/6/2025 (Estimated)DNAGinkgo Bioworks-$547.03M-$9.16N/AN/AN/A-198.84%-52.35%-27.14%8/14/2025 (Estimated)IPHYFInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/A9/17/2025 (Estimated)RLAYRelay Therapeutics-$337.71M-$2.23N/AN/AN/AN/A-44.17%-39.53%8/5/2025 (Estimated)Latest IPHYF, DNA, CGEM, and RLAY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CGEMCullinan Therapeutics-$0.78-$0.74+$0.04-$0.74N/AN/A5/6/2025Q1 2025DNAGinkgo Bioworks-$1.23-$1.58-$0.35-$1.68$38.70 million$48.32 million5/5/2025Q1 2025RLAYRelay Therapeutics-$0.50-$0.46+$0.04-$0.46$0.01 million$7.68 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGEMCullinan TherapeuticsN/AN/AN/AN/AN/ADNAGinkgo BioworksN/AN/AN/AN/AN/AIPHYFInnate PharmaN/AN/AN/AN/AN/ARLAYRelay TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGEMCullinan TherapeuticsN/A11.6211.62DNAGinkgo BioworksN/A4.884.88IPHYFInnate PharmaN/A2.602.60RLAYRelay TherapeuticsN/A19.9619.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGEMCullinan Therapeutics86.31%DNAGinkgo Bioworks78.63%IPHYFInnate PharmaN/ARLAYRelay Therapeutics96.98%Insider OwnershipCompanyInsider OwnershipCGEMCullinan Therapeutics7.16%DNAGinkgo Bioworks9.72%IPHYFInnate Pharma31.89%RLAYRelay Therapeutics4.87%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGEMCullinan Therapeutics3059.01 million54.79 millionOptionableDNAGinkgo Bioworks64058.53 million52.84 millionOptionableIPHYFInnate Pharma17983.83 million57.10 millionNot OptionableRLAYRelay Therapeutics330171.45 million163.10 millionOptionableIPHYF, DNA, CGEM, and RLAY HeadlinesRecent News About These CompaniesRelay Therapeutics, Inc. (RLAY) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comBofA Reiterates a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PTJune 24, 2025 | insidermonkey.comRelay Therapeutics (NASDAQ:RLAY) Stock Price Down 4.9% - Time to Sell?June 20, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Stock Price Up 5.7% - Here's What HappenedJune 18, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Shares Gap Down - Here's What HappenedJune 13, 2025 | marketbeat.comRelay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of DirectorsJune 11, 2025 | globenewswire.comRelay Therapeutics (NASDAQ:RLAY) Trading 6.7% Higher - What's Next?June 10, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Moderate Buy" from AnalystsJune 10, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Sees Large Growth in Short InterestJune 5, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by Bank of America Corp DEJune 4, 2025 | marketbeat.comSquarepoint Ops LLC Increases Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY)June 3, 2025 | marketbeat.comNuveen Asset Management LLC Increases Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY)June 3, 2025 | marketbeat.comJane Street Group LLC Cuts Stock Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)June 3, 2025 | marketbeat.comRelay Therapeutics’ RLY-2608 Shows Promising 11-Month PFS in Breast CancerJune 2, 2025 | msn.comRelay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025June 2, 2025 | globenewswire.comTwo Sigma Investments LP Sells 199,482 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)May 31, 2025 | marketbeat.comRelay Therapeutics (NASDAQ:RLAY) Shares Up 5.1% - Here's What HappenedMay 30, 2025 | marketbeat.comRelay Therapeutics to Participate in Two Upcoming Investor Conferences in JuneMay 29, 2025 | globenewswire.comRelay Therapeutics’ SWOT analysis: ai-driven biotech stock faces pivotal yearMay 29, 2025 | investing.comVoloridge Investment Management LLC Cuts Stock Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)May 29, 2025 | marketbeat.comWhat Makes Relay Therapeutics (RLAY) a New Buy StockMay 23, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIPHYF, DNA, CGEM, and RLAY Company DescriptionsCullinan Therapeutics NASDAQ:CGEM$7.76 +0.01 (+0.13%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$7.75 -0.01 (-0.13%) As of 06/27/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Ginkgo Bioworks NYSE:DNA$9.42 -0.19 (-2.01%) Closing price 06/27/2025 03:59 PM EasternExtended Trading$9.38 -0.04 (-0.39%) As of 06/27/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Innate Pharma OTCMKTS:IPHYF$1.95 0.00 (0.00%) As of 06/27/2025Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Relay Therapeutics NASDAQ:RLAY$3.30 -0.02 (-0.60%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$3.30 0.00 (0.00%) As of 06/27/2025 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
